Search Videos and More
New International Partnership to Accelerate Search for Cancer Cures
Cancer patients in Australia and the United States will benefit from a new research-focused collaboration between the Peter MacCallum Cancer Centre and Dana-Farber Cancer Institute in Boston.Dana-Farber Cancer Institute Faculty Among World’s Most Highly Cited Researchers
Dana-Farber Cancer Institute is proud to announce that 33 of its researchers have been named to the Highly Cited Researchers list of 2022 released today by the Institute for Scientific Information at Clarivate.Study Shows That Immune System Holds Clues to Patients With High-Risk Smoldering Myeloma Likely to Benefit From Treatment
In a new study, investigators at Dana-Farber Cancer Institute demonstrate that changes in immune system cells can indicate which patients with high-risk "smoldering" myeloma are likely to progress to myeloma and which will benefit the most from treatment.Research Update for Triple Negative MBC | 2021-2022 EMBRACE MBC Virtual Forum Series
Antonio Giordano, MD, PhD; Sarah Sammons, MD; and Morgan Rutter, MS, BSN, RN, discuss advances in research and treatment for patients with triple negative metastatic breast cancer.Research Updates - Metastatic Breast Cancer
In the following videos, faculty from Dana-Farber Cancer Institute review research updates from the 2022-2023 EMBRACE Metastatic Breast Cancer Patient Forum Series.Three of the World’s Top Research Institutions Join Forces to Drive Progress Against Pediatric Cancer
Large-scale collaboration will leverage each institution’s expertise and infrastructure to advance understanding of the biological basis of pediatric cancers, identify new vulnerabilities of these diseases and accelerate cures globally.Study Finds Individuals With Inflammatory Breast Cancer at Higher Risk of Cancer Spread to the Brain
New research from Dana-Farber Cancer Institute indicates that among individuals with breast cancer, those with a rare subtype called inflammatory breast cancer face a higher risk that their cancer will spread, or metastasize, to the brain.Computer Platform Helps Match Patients With Cancer to Trials of Targeted Therapy
MatchMiner shortens time to identify appropriate precision medicine trials for individual patientsDana-Farber’s Kornelia Polyak Elected to the National Academy of Medicine
Kornelia Polyak, M.D., Ph.D., professor of medicine, medical oncology, Dana-Farber Cancer Institute has been elected to the prestigious National Academy of Medicine.Kornelia Polyak Wins Prestigious American Cancer Society Award
Kornelia Polyak, MD, PhD, a breast cancer researcher at Dana-Farber Cancer Institute and Professor of Medicine at Harvard Medical School is the recipient of the American Cancer Society’s prestigious Research Professor Award.Adjuvant Olaparib for BRCA1/2 Variant Carriers
The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings on May 6, May 20, June 1, and August 5, 2022 to discuss recommendations for the use of adjuvant olaparib for high-risk, breast cancer in BRCA1/2 carriers.Symposium Highlights 75 Years of Dana-Farber Science